Oral Amiodarone Therapy in Dogs with Atrial Fibrillation
Department of Small Animal Clinical Sciences and the Michael E DeBakey Institute, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station 77843-4474, USA. Journal of Veterinary Internal Medicine
(Impact Factor: 1.88).
07/2006; 20(4):921-6. DOI: 10.1111/j.1939-1676.2006.tb01806.x
The medical records of client-owned dogs in which amiodarone was used to manage atrial fibrillation (AF) were reviewed. Data analyzed included signalment, history of heart failure, presenting complaint, clinical diagnosis, prescription drug history, number of re-examinations, outcome, and laboratory analysis including serum biochemical analysis, CBC, and thyroid function testing. Specific data for amiodarone included loading and maintenance dose, duration of loading dose, adverse effects, and reason for decreasing dose or discontinuation of amiodarone therapy. Follow-up data for 17 dogs were included in the analysis. Various cardiac diseases including cardiomyopathy, valvular endocardiosis, and congenital heart disease were diagnosed in the dogs. Median loading and maintenance dosages of amiodarone were 16.5 and 9.0 mg/kg of body weight/d, respectively. A >20% decrease in heart rate was achieved in 13 dogs (76%). Conversion to sinus rhythm was achieved and maintained in 6 dogs (35%). Amiodarone was discontinued in 5 dogs, and the dose was decreased because of symptomatic bradycardia (n = 1), asymptomatic (n = 1) and symptomatic (n = 3) increases in hepatic enzyme activities, and for unknown reason (n = 1). On the basis of >20% decrease in heart rate in 76% of the dogs and conversion to sinus rhythm in 35%, it was concluded that amiodarone may be useful in managing AF in dogs. The use of amiodarone in the medical management of AF in dogs warrants further investigation.
Available from: univ-toulouse.fr
[Show abstract] [Hide abstract]
ABSTRACT: L'auteur explique dans une première partie le fonctionnement normal de l'onde de dépolarisation cardiaque et la genèse de la fibrillation atriale chez les chevaux. Les différentes causes sont répertoriées, puis une démarche diagnostique est proposée aux lecteurs : de l'auscultation cardiaque caractéristique à l'échocardiographie, en passant par l'électrocardiographie. Le traitement à base de sulfate de quinidine par voie orale est largement détaillé, avant d'envisager les autres traitements existants. La deuxième partie est une étude rétrospective sur 9 chevaux dont un diagnostic de fibrillation atriale idiopathique a été posé à l'ENVT de 2002 à 2006. Le matériel et la méthode sont d'abord détaillés puis les résultats des diagnostics et des traitements effectués avec du sulfate de quinidine per os sont donnés. Cette étude donne 89 % de réussite au traitement, avec des chevaux qui reviennent à un niveau antérieur de compétition.
Journal of the American Veterinary Medical Association 04/2008; 232(5):684-6. DOI:10.2460/javma.232.5.684 · 1.56 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: A 4-year-old, intact male Dogue de Bordeaux dog with congenital valvular pulmonic stenosis, tricuspid valve dysplasia, and chronic atrial fibrillation underwent ultrasound-guided balloon valvuloplasty in addition to pharmacological treatment. Owner compliance to prescribed pharmacotherapy proved very poor, and concerns developed regarding the ability to successfully control heart rate and symptoms using drug therapy alone. These concerns were addressed by the implantation of a novel vagal stimulation system that was programmed to prevent a ventricular rate of >145 bpm. Consequently, post-operative ventricular response rate decreased from up to 250 to 140 bpm. Successful ventricular rate control was maintained for 291 days post-operatively, following which euthanasia was elected by the owner due to persistent right-sided congestive heart failure. To the authors' knowledge, this is the first report of successful continuous rate control using a vagal stimulating system in a closed-chest, client-owned dog with chronic atrial fibrillation secondary to spontaneously occurring organic heart disease.
Journal of veterinary cardiology: the official journal of the European Society of Veterinary Cardiology 11/2008; 10(2):147-54. DOI:10.1016/j.jvc.2008.09.004 · 1.32 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.